Sean Bohen, M.D., Ph.D., is the President and Chief Executive Officer at OLEMA PHARMACEUTICALS INC, a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Dr. Bohen brings a wealth of experience in oncology drug development and leadership to his role at Olema. He holds both a medical degree and a doctorate in biochemistry from the University of California, San Francisco, and completed his residency in internal medicine at Massachusetts General Hospital. Prior to joining Olema, Dr. Bohen held several high-profile positions in the biopharmaceutical industry. He served as the Chief Medical Officer at IDEAYA Biosciences, where he played a pivotal role in advancing the company's oncology pipeline. Before that, he was the Executive Vice President and Head of Global Development at Clovis Oncology, where he oversaw the development and regulatory approval of Rubraca, a PARP inhibitor for the treatment of ovarian cancer. Dr. Bohen's career also includes significant contributions at Genentech, where he held various roles in clinical development and medical affairs, contributing to the development of several successful cancer therapies. As President and CEO of Olema Pharmaceuticals, Dr. Bohen leads the company's strategic direction and oversees the development of its lead candidate, OP-1250, a novel complete estrogen receptor antagonist (CERAN) for the treatment of ER-positive, HER2-negative breast cancer. Under his leadership, Olema has made significant progress in advancing its clinical programs and strengthening its position in the field of women's oncology. Dr. Bohen's extensive experience in drug development, combined with his dedication to improving patient outcomes, makes him a driving force in Olema's mission to deliver innovative treatments for women's cancers.